Tyra Biosciences Inc has a consensus price target of $23.33 based on the ratings of 7 analysts. The high is $28 issued by Oppenheimer on July 3, 2024. The low is $12 issued by HC Wainwright & Co. on June 23, 2022. The 3 most-recent analyst ratings were released by Oppenheimer, Wedbush, and HC Wainwright & Co. on July 3, 2024, respectively. With an average price target of $26.33 between Oppenheimer, Wedbush, and HC Wainwright & Co., there's an implied 33.47% upside for Tyra Biosciences Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
07/03/2024 | Buy Now | 41.92% | Oppenheimer | Matthew Biegler | $28 → $28 | Reiterates | Outperform → Outperform | Get Alert |
07/03/2024 | Buy Now | 41.92% | Wedbush | Robert Driscoll | $28 → $28 | Reiterates | Outperform → Outperform | Get Alert |
07/03/2024 | Buy Now | 16.57% | HC Wainwright & Co. | Mitchell Kapoor | $23 → $23 | Reiterates | Buy → Buy | Get Alert |
06/05/2024 | Buy Now | 16.57% | HC Wainwright & Co. | Mitchell Kapoor | $23 → $23 | Reiterates | Buy → Buy | Get Alert |
05/13/2024 | Buy Now | 41.92% | Oppenheimer | Matthew Biegler | $25 → $28 | Reiterates | Outperform → Outperform | Get Alert |
05/10/2024 | Buy Now | 41.92% | Wedbush | Robert Driscoll | → $28 | Reiterates | Outperform → Outperform | Get Alert |
05/10/2024 | Buy Now | 16.57% | HC Wainwright & Co. | Mitchell Kapoor | → $23 | Reiterates | Buy → Buy | Get Alert |
03/21/2024 | Buy Now | 41.92% | Wedbush | Robert Driscoll | → $28 | Reiterates | Outperform → Outperform | Get Alert |
03/20/2024 | Buy Now | 16.57% | HC Wainwright & Co. | Mitchell Kapoor | $19 → $23 | Reiterates | Buy → Buy | Get Alert |
12/29/2023 | Buy Now | 36.85% | Wedbush | Robert Driscoll | $27 → $27 | Reiterates | Outperform → Outperform | Get Alert |
12/26/2023 | Buy Now | -3.7% | HC Wainwright & Co. | Mitchell Kapoor | → $19 | Reiterates | Buy → Buy | Get Alert |
11/08/2023 | Buy Now | -3.7% | HC Wainwright & Co. | Mitchell Kapoor | $20 → $19 | Maintains | Buy | Get Alert |
08/11/2023 | Buy Now | 36.85% | Wedbush | Robert Driscoll | → $27 | Reiterates | Outperform → Outperform | Get Alert |
08/11/2023 | Buy Now | 1.37% | HC Wainwright & Co. | Mitchell Kapoor | $17 → $20 | Maintains | Buy | Get Alert |
08/01/2023 | Buy Now | -13.84% | HC Wainwright & Co. | Mitchell Kapoor | → $17 | Reiterates | Buy → Buy | Get Alert |
06/30/2023 | Buy Now | 36.85% | Wedbush | Robert Driscoll | → $27 | Initiates | → Outperform | Get Alert |
05/08/2023 | Buy Now | 26.71% | Oppenheimer | Matthew Biegler | → $25 | Reiterates | → Outperform | Get Alert |
05/05/2023 | Buy Now | -13.84% | HC Wainwright & Co. | Mitchell Kapoor | → $17 | Reiterates | → Buy | Get Alert |
03/23/2023 | Buy Now | -13.84% | HC Wainwright & Co. | Mitchell Kapoor | → $17 | Reiterates | → Buy | Get Alert |
03/07/2023 | Buy Now | -13.84% | HC Wainwright & Co. | Mitchell Kapoor | $15 → $17 | Maintains | Buy | Get Alert |
03/02/2023 | Buy Now | -23.97% | HC Wainwright & Co. | Mitchell Kapoor | $12 → $15 | Maintains | Buy | Get Alert |
02/03/2023 | Buy Now | -13.84% | Oppenheimer | Matthew Biegler | → $17 | Initiates | → Outperform | Get Alert |
06/23/2022 | Buy Now | -39.18% | HC Wainwright & Co. | Raghuram Selvaraju | → $12 | Initiates | → Buy | Get Alert |
03/08/2022 | Buy Now | 36.85% | Jefferies | Maury Raycroft | $31 → $27 | Upgrade | Hold → Buy | Get Alert |
11/08/2021 | Buy Now | 57.12% | Jefferies | Maury Raycroft | — | Downgrade | Buy → Hold | Get Alert |
10/11/2021 | Buy Now | 11.51% | B of A Securities | Geoff Meacham | — | Initiates | → Buy | Get Alert |
10/11/2021 | Buy Now | -3.7% | Jefferies | Maury Raycroft | — | Initiates | → Buy | Get Alert |
10/11/2021 | Buy Now | — | Cowen & Co. | Tyler Van Buren | — | Initiates | → Outperform | Get Alert |
The latest price target for Tyra Biosciences (NASDAQ:TYRA) was reported by Oppenheimer on July 3, 2024. The analyst firm set a price target for $28.00 expecting TYRA to rise to within 12 months (a possible 41.92% upside). 15 analyst firms have reported ratings in the last year.
The latest analyst rating for Tyra Biosciences (NASDAQ:TYRA) was provided by Oppenheimer, and Tyra Biosciences reiterated their outperform rating.
The last upgrade for Tyra Biosciences Inc happened on March 8, 2022 when Jefferies raised their price target to $27. Jefferies previously had a hold for Tyra Biosciences Inc.
The last downgrade for Tyra Biosciences Inc happened on November 8, 2021 when Jefferies changed their price target from $19 to $31 for Tyra Biosciences Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tyra Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tyra Biosciences was filed on July 3, 2024 so you should expect the next rating to be made available sometime around July 3, 2025.
While ratings are subjective and will change, the latest Tyra Biosciences (TYRA) rating was a reiterated with a price target of $28.00 to $28.00. The current price Tyra Biosciences (TYRA) is trading at is $19.73, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.